Manage Account
Change Password
Sign Out
UserName
Profession Email
Profession Email
|
Indications/Uses
Listed in Dosage.
|
|
Dosage/Direction for Use
Adult: PO Bradycardia ≤240 mg/day in divided doses. Chronic management of reversible airways obstruction 20 mg 3-4 times/day. IV Bradycardia 250-500 mcg. Inhalation Acute bronchospasm As metered-dose inhaler releasing 750 mcg/inhalation: 1-2 inhalations; repeat if needed. Max: 12 inhalations/24 hr. As 5% soln from a hand nebuliser: 10 inhalations.
|
|
Administration
May be taken with or without food.
|
|
Contraindications
Cardiac arrhythmias associated with tachycardia.
|
|
Special Precautions
CV disease (e.g. arrhythmia, hypertension, CHF), DM, glaucoma, hyperthyroidism, hypokalaemia, seizure disorders. Pregnancy and lactation.
|
|
Adverse Reactions
Tachycardia, nervousness, increased serum glucose, increased potassium levels, tremor, palpitation, headache, dizziness, insomnia, nausea, vomiting, bad taste, heartburn, xerostomia, trembling, muscle cramps, weakness, coughing, pharyngitis, increased diaphoresis, paradoxical bronchospasm, hypertension, chest pain, angina, drowsiness, diarrhoea, taste change.
|
|
Drug Interactions
Effects may be antagonised by β-blockers e.g. propranolol. Duration of bronchodilation may be increased with inhaled ipratropium. Increased adverse effects with MAOIs, TCAs, sympathomimetics.
|
|
CIMS Class
|
|
ATC Classification
R03AB03 - orciprenaline ; Belongs to the class of adrenergic inhalants, non-selective beta-adrenoreceptor agonists. Used in the treatment of obstructive airway diseases.
R03CB03 - orciprenaline ; Belongs to the class of adrenergics for systemic use, non-selective beta-adrenoreceptor agonists. Used in the treatment of obstructive airway diseases. |
